{
  "image_filename": "table_p2_det_1_011.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_011.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_011",
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "supports_claim": false,
  "explanation": "Extract of a table showing local and systemic solicited adverse event percentages (pain, redness, swelling, fatigue, headache, muscle pain, joint pain, shivers, nausea, fever) for Flublok and comparator/placebo cohorts, with footnotes describing data rounding, cohort definitions, and fever grading. does not support the claim because the table presents safety/reactogenicity data only and contains no measurements of cross-reactive antibody levels or immunogenicity comparisons of BEVS-derived versus egg-derived HA antigens Note: None",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Extract of a table showing local and systemic solicited adverse event percentages (pain, redness, swelling, fatigue, headache, muscle pain, joint pain, shivers, nausea, fever) for Flublok and comparator/placebo cohorts, with footnotes describing data rounding, cohort definitions, and fever grading.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table presents safety/reactogenicity data only and contains no measurements of cross-reactive antibody levels or immunogenicity comparisons of BEVS-derived versus egg-derived HA antigens",
    "confidence_notes": "None"
  }
}